Navigation Links
Debiopharm Signs License Agreement for Marketing of Salvacyl(R)/Moapar(R) 3-Month in Treatment of Sexual Deviations

LAUSANNE, Switzerland, May 15 /PRNewswire/ -- Debiopharm Group (Debiopharm), a global independent biopharmaceutical development specialist focusing on serious medical conditions and particularly oncology, announced the signature of a license agreement with its long-term European pharmaceutical partner, for the marketing of Salvacyl(R)/Moapar(R) 3-month formulation, a gonadotropin releasing hormone (GnRH) agonist analogue, effective in the treatment of severe sexual deviations in adult men by inducing and maintaining a reversible reduction of testosterone to castrate serum levels. Debiopharm has developed and received marketing authorisations for Salvacyl / Moapar in nine major European countries, including France, Germany, UK, Sweden, Norway, Denmark, Belgium, the Netherlands and Finland.

"There is a genuine unmet medical and social need for the treatment of sexual deviations. Not many pharma companies are willing or courageous enough to provide this type of treatment but we feel that we have a responsibility to help doctors and patients with the tools they need, even if it is difficult or controversial," said Rolland-Yves Mauvernay, President and Founder of Debiopharm Group.

About Salvacyl(R)/Moapar(R)

In the treatment of sexual deviations in men, administration of Salvacyl(R)/Moapar(R) every 3 months is an advantage over daily oral forms or intra-muscular weekly injections required with antiandrogens such as cyproterone acetate (CPA) and medroxyprogesterone acetate (MPA) and there are fewer side effects.

Two studies have shown that regular injections of the active ingredient, triptorelin, over a period of eight months to seven years in male patients with sexual deviations demonstrated a good efficacy and safety profile. Triptorelin produced reversible serum castrate testosterone levels (defined as less than or equal to 1.735 nmol/L) in all patients, and concurrently with the decrease in testosterone levels, triptorelin treatment reduced deviant sexual behaviours in 35/36 patients with severe sexual deviations.

About Debiopharm Group

Debiopharm Group is a global biopharmaceutical development specialist that in-licenses promising biologics and small molecule drug candidates. Debiopharm develops its products for global registration and maximum commercial potential for out-licensing to pharmaceutical partners for sales and marketing.

Debiopharm independently funds the worldwide development of all of its products while providing expertise in pre-clinical and clinical trials, manufacturing, drug delivery and formulation, and regulatory affairs.

Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharm has developed three products with global combined sales in excess of $2.65 billion in 2007.

For more information on Debiopharm Group, please visit:

Debiopharm S.A. Contacts

Kim Bill

VP, Corporate Development

Tel.: +41(0)21-321-01-11

Fax: +41(0)21-321-01-69

Additional Media Contacts

In London


Brian Hudspith

Tel: +44(0)20-7379-5151

In New York

Russo Partners, LLC

Wendy Lau

Tel: +1-212-845-4272

Fax: +1-212-845-4260

SOURCE The Debiopharm Group
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Debiopharm and EPFL Establish an Oncology Chair
2. Japanese Cancer Association and Debiopharm Honour Professors Minoru Toyota and Keiichi Nakayama With the 2007 JCA-Mauvernay Award
3. Debiopharm Receives cGMP Certification for Quality Control of its Drug Products
4. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
5. NuVasive Signs Definitive Agreement to Acquire Osteocel Biologics Business from Osiris Therapeutics
6. Quintiles Signs Agreement to Acquire Eidetics
7. ImaRx Therapeutics Signs Letter of Intent With Microbix Biosystems for the Sale of Urokinase
8. Assay Designs(TM) Announces Collaboration with Medical University of South Carolina (MUSC)
9. Botaneco signs feasibility agreement with Croda to develop specialty crop oil formulation
10. DelSite Signs Technology Evaluation Agreement With Global Pharmaceutical Company for GelSite(R) Polymer
11. Leslie J. Browne Resigns as President and Chief Executive Officer of Pharmacopeia, Inc.
Post Your Comments:
(Date:11/25/2015)... November 25, 2015 Studies reveal ... human plaque and pave the way for more effective treatment ... cats     --> ... diagnosed health problems in cats, yet relatively little was understood ... collaborative studies have been conducted by researchers from the WALTHAM ...
(Date:11/25/2015)... , Nov. 25, 2015 /PRNewswire/ - Aeterna Zentaris Inc. ... its business and prospects remain fundamentally strong and ... (zoptarelin doxorubicin) recently received DSMB recommendation to continue ... following review of the final interim efficacy and ... Primary Endpoint in men with heavily pretreated castration- ...
(Date:11/25/2015)... PORTLAND, Oregon , November 25, 2015 /PRNewswire/ ... Deep Market Research Report is a professional and ... Genomics industry.      (Logo: ... basic overview of the industry including definitions, classifications, ... analysis is provided for the international markets including ...
(Date:11/24/2015)... ... November 24, 2015 , ... The United States Golf ... the 2016 USGA Green Section Award. Presented annually since 1961, the USGA Green Section ... her work with turfgrass. , Clarke, of Iselin, N.J., is an extension ...
Breaking Biology Technology:
(Date:11/18/2015)... PHILADELPHIA , Nov. 18, 2015  As new ... in children, doctors and other healthcare providers face challenges ... counsel families and patients. In addition, as more children ... into a patient,s adulthood and old age. ... The Children,s Hospital of Philadelphia (CHOP) . ...
(Date:11/17/2015)... Calif. , Nov. 17, 2015  Vigilant Solutions ... has joined its Board of Directors. ... Board after recently retiring from the partnership at TPG ... 107 companies with over $140 Billion in revenue.  He ... improvement across all the TPG companies, from 1997 to ...
(Date:11/12/2015)... Nov. 12, 2015  Arxspan has entered into ... and Harvard for use of its ArxLab cloud-based ... tools. The partnership will support the institute,s efforts ... chemical research information internally and with external collaborators. ... for managing the Institute,s electronic laboratory notebook, compound ...
Breaking Biology News(10 mins):